Series B Finance-Round

New round of financing for CureVac GmbH Euro 22 million for cancer research and treatment

SAP founder Dietmar Hopp invests in Tübingen biotech company

(Stuttgart/Tübingen) CureVac GmbH, a Tübingen-based biopharmaceutical company focusing on the development of drugs to combat cancer, has completed its second round of financing. Its new investors are DH Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG, investment companies owned by the family of SAP co-founder Dietmar Hopp. These investors will contribute as much as Euro 22 million over the coming years. The new capital will allow CureVac to demonstrate the clinical effectiveness of its main product RNActive™ and put together a solid development portfolio, explains Dr. Ingmar Hoerr, co-founder and CEO of CureVac. Dr. Hoerr is expecting additional impetus from the support provided by entrepreneur and biochemist Dr. Friedrich von Bohlen, who will now be joining the advisory board in the capacity of investor representative.
As a biopharmaceutical research organisation focusing on the discovery and development of innovative active ingredients with clinical significance in the fields of oncology and infectious diseases, CureVac GmbH was already a particularly promising biotech company. According to Dr. Klaus Eichenberg, Managing Director of BioRegio STERN Management GmbH, this significant investment should also be seen as an acknowledgement of what Tübingen and the entire STERN region have to offer. We believe that the future holds great market opportunities for immunotherapeutic methods, and CureVac GmbHs GMP labs will be key to its business success, he states.
CureVac will have secure funding for the foreseeable future thanks to the strong commitment of the Hopp family, which is also taking over the shares of Leonardo Venture GmbH & Co. KGaA. This means that the Phase 2 clinical trials with stabilised and physiologically active messenger ribonucleic acid (RNActive™) can now be completed.